CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-07-07 | Metzger Michael A Chief Executive Officer | Sale | −100 | $21.00 | $2K | 17,659 |
| 2022-07-07 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −100 | 0 | ||
| 2022-07-06 | Metzger Michael A Chief Executive Officer | Option exercise | +15,009 | $6.38 | $96K | 32,668 |
| 2022-07-06 | Metzger Michael A Chief Executive Officer | Sale | −15,009 | $21.07 | $316K | 17,659 |
| 2022-07-06 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −15,009 | 0 | ||
| 2022-07-01 | Morrison Briggs President, Head of R&D | Option exercise | +62,292 | $7.20 | $449K | 80,128 |
| 2022-07-01 | Morrison Briggs President, Head of R&D | Sale | −62,292 | $19.00 | $1.2M | 17,836 |
| 2022-07-01 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −62,292 | 0 | ||
| 2022-06-13 | Goldan Keith A. Chief Financial Officer | Grant or award | +3,205 | 3,205 | ||
| 2022-06-13 | Goldan Keith A. Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +230,000 | $15.60 | $3.6M | 230,000 |
| 2022-04-04 | Morrison Briggs President, Head of R&D | Option exercise | +3,128 | $7.20 | $23K | 20,964 |
| 2022-04-04 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −3,128 | 0 | ||
| 2022-04-04 | Morrison Briggs President, Head of R&D | Option exercise | +3,128 | $10.90 | $34K | 20,964 |
| 2022-04-04 | Morrison Briggs President, Head of R&D | Sale | −3,128 | $18.29 | $57K | 17,836 |
| 2022-04-04 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −3,128 | 0 | ||
| 2022-04-01 | Morrison Briggs President, Head of R&D | Option exercise | +70,545 | $7.20 | $508K | 88,381 |
| 2022-04-01 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −70,545 | 0 | ||
| 2022-04-01 | Morrison Briggs President, Head of R&D | Sale | −6,000 | $17.44 | $105K | 42,336 |
| 2022-04-01 | Morrison Briggs President, Head of R&D | Sale | −24,500 | $17.44 | $427K | 17,836 |
| 2022-04-01 | Morrison Briggs President, Head of R&D | Option exercise | +70,545 | $10.90 | $769K | 88,381 |
Page 14 of 15 · 290 trades